Endo International (ENDP) has been falling long and hard – from a high of $96 in 2015 to a low of $1.95 in 2019.
Entangled in lawsuits related to opioid marketing and ensnared by competition in the generics business, Endo now majorly banks upon its specialty pharmaceutical business to deliver blockbuster returns.
It's hard to find bullish reasons to put money to work now in the stock.
I have always stuck up for Western medicine. You can chew all the celery you want, but without antibiotics, three quarters of us would not be here. ~ Hugh Laurie
Endo International’s (ENDP)